Aurobindo Pharma reports robust Q2FY26 growth

Aurobindo Pharma Limited today announced its unaudited standalone and consolidated financial results for Q2FY26 and the half year ended September 30, 2025. Consolidated revenue from operations increased by 6.3% year-over-year to INR 8,286 Cr, with a net profit of INR 848 Cr, up 3.8% year-over-year. EBITDA (before Forex and Other Income) stood at INR 1,678 Cr, reflecting a margin of 20.3%.

Geographically, US formulations revenue grew by 3.1% to INR 3,638 Cr, Europe formulations by 17.8% to INR 2,480 Cr, and Growth Markets by 8.7% to INR 882 Cr. The company also reported a strong net cash position of $170 million as of September 30, 2025, and generated $57 million in free cash flows.

Regulatory achievements include 13 ANDA filings with the USFDA, 7 product approvals, and 6 product launches in the US market during the quarter. The company also announced successful Phase 3 endpoints for its BP16 (Prolia biosimilar) and is on track for other biosimilar milestones, with filings targeting immunology and oncology biosimilars planned through FY27.